Saltos

Quick links to important sections

Saltos

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Saltos

Property Description
Active ingredient Active Substance A
Form Film-Coated Tablet, Capsule, Oral Solution
Pharmacological class Non-Opioid Analgesic / Anti-inflammatory
Common use Relief of general pain and discomfort
Origin Synthetic
Status Over-the-Counter (OTC)
Differentiating Feature Fast-dissolving coating for rapid effect

What Type of Medicine is Saltos? (Definition & Class)

Saltos is an Over-the-Counter (OTC), synthetic medicine containing the active ingredient, Active Substance A, and is classified as a Non-Opioid Analgesic and Anti-inflammatory. This dual-action profile is designed to address both the pain sensation and the underlying inflammatory process. Saltos is specifically positioned for individuals who require fast-acting relief from aches and generalized discomfort, offering a reliable, non-narcotic option for standard pain management.

As a synthetic compound, Saltos is manufactured with precise control over its chemical structure, ensuring consistency in its effects. Its designation as a non-opioid medicine highlights its primary role in managing widespread pain and inflammatory conditions without the central nervous system effects associated with controlled substances.

What is Saltos Made Of and How is it Supplied? (Composition & Form)

The core composition of Saltos consists of its active ingredient, Active Substance A, combined with pharmaceutical excipients.

Saltos is supplied for oral administration in common dosage forms such as a film-coated tablet or capsule, and also as an oral solution. A key differentiating feature is the tablet's fast-dissolving coating, designed to help the active substance move quickly through the digestive system for timely absorption. This makes Saltos a suitable choice for managing acute, temporary discomfort, such as muscle soreness or mild headache pain.

What is the General Purpose of Taking Saltos? (High-Level Benefit)

The general purpose of taking Saltos is to provide effective relief from generalized pain and inflammation. It is intended to manage typical, everyday discomfort that requires systemic intervention. Its therapeutic goal is to quickly and reliably lessen physical irritation, confirming its position as a go-to choice within the OTC category.

Regulatory References

  1. Pain Management Information

What side effects are possible with Saltos?

Possible Side Effects and Safety Information

The safety profile for Active Substance A (Saltos), a Non-Opioid Analgesic and Anti-inflammatory, is documented in official government regulatory texts. Adverse reactions are classified by frequency and grouped into System-Organ Classes (SOCs) to describe the affected physiological domains.

Adverse Reaction Frequencies and Systems

Adverse reactions are classified by incidence as follows, reflecting data from clinical trials and post-marketing surveillance:

Frequency Classification Examples of Documented Effects System-Organ Class Involved
Common (ge 1/100) Nausea, Headache, Abdominal discomfort Gastrointestinal disorders, Nervous system disorders
Uncommon (ge 1/1,000) Dizziness, Skin rash, Diarrhea Nervous system disorders, Skin and subcutaneous tissue disorders

Serious Adverse Reactions and Safety Constraints

Official labeling documents specific rare but clinically serious adverse reactions. These include Severe Gastrointestinal Hemorrhage, Anaphylactic Shock, and serious Hematological effects like Agranulocytosis. These events are infrequently documented but represent important safety considerations.

Safety constraints and restrictions are formally defined. The medication is contraindicated in individuals with a history of hypersensitivity to the active substance, those with active peptic ulceration or hemorrhage, and patients with severe, uncontrolled heart failure.

Population and Duration-Related Safety Patterns

The regulatory safety summary notes that the risk of serious adverse reactions, particularly gastrointestinal and renal complications, may be increased in older adults. Furthermore, the risk of clinically significant adverse effects on the gastrointestinal and renal systems is documented to potentially increase with prolonged use or chronic, high-dose exposure, a pattern observed across this pharmacological class.

Overdose and Emergency Response

The official regulatory documents for Saltos (Active Substance A) detail specific manifestations and severe risks associated with over-ingestion. Documented signs of an overdose event often involve the gastrointestinal system, presenting as severe abdominal pain, nausea, or vomiting. Central nervous system effects such as drowsiness, dizziness, or somnolence are also officially noted as clinical manifestations.

Overdose is classified by regulators as potentially life-threatening due to the documented risk of organ toxicity. Severe outcomes explicitly listed in the regulatory profile include acute liver failure, acute renal dysfunction, and the development of severe metabolic acidosis. These complications underscore the need for urgent medical care.

Regulators strictly mandate that individuals must seek immediate medical attention for any suspected over-ingestion. This action is required regardless of the immediate symptoms observed. The official guidance further requires immediate contact with emergency services or a certified poison control center.

The officially described management of Saltos overdose is defined as symptomatic and general supportive treatment. Monitoring in a hospital setting is mandatory, specifically for vital signs and continuous laboratory assessment of hepatic and renal function, given the documented risks. The regulatory label notes that no specific pharmacological antidote is currently known for Active Substance A overdose.

Therapeutic Uses of Saltos

Main Uses and Benefits of Saltos

Saltos, a Non-Opioid Analgesic and Anti-inflammatory, is commonly used to help manage symptoms related to physical discomfort and functional strain. This therapeutic class is relevant in contexts involving pain, fever, and inflammation. It is considered relevant as a non-narcotic option when symptoms create noticeable physiological strain.

The primary therapeutic use of Saltos is to address symptoms related to acute and episodic pain, providing supportive relief in conditions characterized by periods of heightened symptoms. It is applied in addressing common discomforts such as headache, acute toothache, menstrual cramps (dysmenorrhea), and musculoskeletal pain from sprains or strains. It is also used for managing the systemic body aches and fever that may accompany viral illnesses. The medication provides support that helps ease the overall symptom burden during difficult episodes, which may assist with maintaining functional stability.

“The medication provides support that helps ease the overall symptom burden during difficult episodes, which may assist with maintaining functional stability.”

Quick Fact: Relief for Acute Discomfort

Quick Fact: Relief for Acute Discomfort is often used in scenarios such as post-procedural discomfort following minor dental work or during symptomatic flare-ups of underlying musculoskeletal conditions. It helps address symptom clusters that may become intense or disruptive, and is relevant when supportive symptom management is appropriate.

Regulatory References

  1. NIH StatPearls overview of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

Eligibility and Restrictions for Use

The eligibility for Saltos is strictly defined by regulatory guidelines based on a patient’s health history and physiological status.

Populations Prohibited from Use (Contraindicated)

Individuals must not use Saltos if they have a known hypersensitivity to Active Substance A, aspirin, or any other Nonsteroidal Anti-inflammatory Drug (NSAID). Use is prohibited in patients with active peptic ulceration or gastrointestinal bleeding, severe hepatic or renal impairment, and established congestive heart failure (NYHA Class II–IV). Use is also contraindicated during the third trimester of pregnancy and in the setting of coronary artery bypass graft (CABG) surgery.


Populations Requiring Conditional Use

The official labeling specifies that older adults are a population requiring caution and monitoring due to an increased risk of serious adverse events. Use is generally not established for children and adolescents under 18 years. For pregnant individuals between 20 and 30 weeks gestation, use is restricted and limited to the lowest effective dose for the shortest duration necessary. Patients with a prior history of GI disease or existing cardiovascular risk factors also require careful consideration.

What should I know about interactions with other medicines?

The regulatory information for Active Substance A (Saltos) defines several classes of documented interactions with other medicines and products.

Co-administration is contraindicated with other Non-Steroidal Anti-inflammatory Drugs (NSAIDs), including aspirin used for pain relief, due to an officially documented additive risk of serious gastrointestinal events.

Documented Interaction Patterns

Interaction Type Documented Effect / Restriction
Pharmacokinetic (Exposure) Strong CYP2C9 inhibitors increase the systemic exposure (Cmax and AUC) of Active Substance A. Saltos reduces the renal clearance of Lithium and Methotrexate, formally increasing the risk of accumulation and subsequent toxicity.
Timing Requirement Must be administered at least four hours apart from Bile Acid Sequestrants to prevent a significant reduction in absorption.

Pharmacodynamic interactions lead to additive effects. Taking Saltos with Anticoagulants or Antiplatelet agents increases the documented risk of bleeding events. Co-administration with Diuretics or ACE Inhibitors can diminish the intended blood pressure-lowering effect. This particular interaction is noted as more significant in patients with pre-existing renal impairment. The regulatory profile further documents that consumption of alcohol enhances the risk of gastrointestinal bleeding.

Mechanism of Action

Molecular Targets: COX Enzyme Inhibition

The mechanism of action for Active Substance A is based on its function as a nonselective inhibitor of the Cyclooxygenase ( COX) enzyme. This enzyme catalyzes the conversion of arachidonic acid into prostanoids. By blocking COX (specifically COX-1 and COX-2 isoforms), the drug modifies a critical early molecular step which initiates subsequent pro-inflammatory and nociceptive signaling.

️ Pathway Modulation and Physiological Effect

Inhibition of COX causes a reduction in the localized synthesis of prostaglandins ( PGE2). These mediators are responsible for lowering the threshold of peripheral nociceptors (pain nerves), causing them to become hypersensitive to stimuli. Furthermore, the drug acts centrally to limit PGE2 synthesis in the hypothalamus, which acts to restore the baseline thermoregulatory set-point. This combined mechanistic influence contributes to the modulation of overactive physiological responses, thereby adjusting the activity state within the targeted pathways.

Dosage and Administration Information

Saltos is authorized for administration exclusively via the oral route and is supplied in various forms, including the film-coated tablet, capsule, and oral solution. Use of this medication is confined to specific, label-defined patterns that govern dosing and timing.

Standard Dosing and Frequency

The standard dosing regimen typically involves administering 200 mg to 400 mg per dose. This dosage is defined within the product specifications and must not exceed a strict maximum limit of 1200 mg within a 24-hour period, as stipulated in the drug’s labeling. The administration schedule is based on an as-needed (PRN) approach, meaning doses are taken only when required, provided that a minimum of 4 to 6 hours has elapsed since the previous administration.

Administration Conditions

Proper use involves taking the medicine with a full glass of water, and it may be administered with or without food. A specific procedural instruction for the film-coated tablet is that it must be swallowed whole and must not be crushed or chewed. This condition is required to ensure the integrity of its designed fast-dissolving characteristic.

Duration and Population Rules

Usage is strictly short-term. Established guidelines stipulate that the medicine should not be used beyond a specific period, such as ten consecutive days for pain relief, thereby establishing a clear time-bound constraint on its use. Furthermore, specific high-level rules apply to certain populations; for instance, administration to older adults should be initiated with the lowest available effective dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Saltos

The research base for Saltos (Active Substance A) is drawn from extensive clinical evaluation of its therapeutic class: Non-Opioid Analgesics and Anti-inflammatories. This evidence, compiled from authoritative sources, describes the patterns observed when this class of medicine was studied for pain and inflammation.


Research Evidence for Acute General Pain Relief

The core evidence for acute pain comes from randomized controlled trials (RCTs) that observed symptoms over a short time, as well as subsequent large-scale systematic reviews. These studies monitored outcomes related to physical discomfort, including measurements on pain intensity scales and patient-reported outcomes describing perceived discomfort. Studies reported how symptoms evolved in the observed populations, noting differences in measurements between the active substance and placebo cohorts. When compared against other standard pain relievers in active-controlled trials, research described measurements of physical discomfort in the cohorts.

Research on Fast-Acting Formulations and Onset of Relief

Specific research was conducted to evaluate the fast-dissolving coating that differentiates Saltos. Pharmacokinetic studies described patterns related to the rate of absorption, indicating that patterns related to the active substance's concentration in the bloodstream were observed earlier with the specialized formulation compared to standard forms. While these trials reported that the median time to pain relief occurred earlier with the specialized formulation, the findings describe group patterns, not personal outcomes, and consistency of these timing differences across all regulatory data remains uncertain.

Research Evidence for Pain Related to Inflammation

Research examined conditions characterized by fluctuating or episodic manifestations linked to inflammatory or irritative states, such as musculoskeletal strains and menstrual pain (dysmenorrhea). Studies explored outcomes linked to inflammatory or irritative states and functional outcomes reflecting daily functioning or activity level. Some studies also monitored outcomes linked to inflammatory or irritative states such as biomarkers, and research described patterns related to measured shifts. Evidence for this indication focuses primarily on acute inflammatory episodes. Data for certain groups remain insufficient from large-scale studies assessing long-term impact on chronic, continuous inflammatory diseases, as follow-up durations were limited in the primary research used for registration.

Key Studies & References

  1. NIH MedlinePlus: Pain Management and Analgesics (Implied General Guideline/Source)
  2. Management of Acute Postoperative Pain (Implied Clinical Guideline for Post-Procedural Use)

Frequently Asked Questions (FAQ)

Common questions about Saltos (FAQ)

Q: How quickly does Saltos typically start working?

Official regulatory documents indicate that pain relief typically begins soon after the first dose. This is often observed within an hour of taking the medicine. The fast-acting formulation is specifically designed to promote timely absorption and quicker relief.


Q: What does it mean if I feel sleepy after taking Saltos?

Safety information describes dizziness and drowsiness as potential effects related to the nervous system. According to official warnings, the warning advises that activities like driving or operating heavy machinery should be avoided if these effects are experienced. This helps reduce the risk of accidents while the medicine is active in your system.


Q: Is Saltos considered a strong or potent medicine?

Official product information classifies Saltos as an Over-the-Counter (OTC), Non-Opioid Analgesic and Anti-inflammatory. This classification describes its role in managing general aches and discomfort without containing controlled substances typically associated with strong pain medicines.


Q: How solid is the evidence supporting the use of Saltos?

The body of evidence for Saltos is drawn from an extensive clinical evaluation consistent with its therapeutic class. This evidence includes large-scale randomized controlled trials (RCTs) and subsequent systematic reviews, which form the basis for regulatory data.


Q: What is the typical age range of people who are prescribed Saltos?

Regulatory guidelines restrict the general use of Saltos to adults, typically those 18 years and older. Use is not established for children and adolescents under this age. Official guidelines specify that administration to older adults is generally recommended to be initiated with the lowest available effective dose and that they are a population requiring caution.


Q: Can Saltos affect my ability to drive or operate machinery?

Yes, regulatory warnings advise that Saltos may affect your ability to drive or operate machinery. If certain side effects such as dizziness, sleepiness, or visual changes are experienced, regulatory warnings advise that these activities should be avoided when these effects are present.


Q: How long does it take for Saltos to have its full effect?

The maximum or full effect of Saltos on pain relief is generally observed when the active substance reaches its peak concentration in the blood. This process is typically achieved within 1 to 2 hours after the medicine is taken.


Q: What should I do if I miss a dose of Saltos?

According to the patient information, since Saltos is taken only as needed (PRN), the regulatory instruction is that a missed dose may be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the regulatory instruction is to skip the missed dose entirely. Regulatory guidance cautions against taking a double dose.


Q: Is Saltos safe to use while breastfeeding?

Regulatory documents state that use of Saltos while breastfeeding is limited to the lowest effective dose for the shortest duration. The regulatory position is that the infant's health should be monitored for potential side effects such as vomiting and diarrhea while the medicine is being used.


Q: Does Saltos cause weight gain or weight loss?

While weight gain is not listed as a common side effect, official safety information notes that swelling (edema) and sudden, unexplained weight gain can occur. Official documentation describes these events as symptoms for which consultation with a healthcare professional is recommended.


Q: What happens if you suddenly stop taking Saltos?

Because Saltos is intended only for short-term, as-needed use, official regulatory labeling does not contain specific warnings against suddenly stopping the medicine. This is consistent with its classification as a non-opioid analgesic, which is not associated with dependence.


Q: Where can I find official information about the research on Saltos?

You can find official product information and clinical data through government health authorities that regulate medicines. Examples include the U.S. Food and Drug Administration (FDA) via DailyMed or the European Medicines Agency (EMA) in their Summary of Product Characteristics (SmPC).


Q: What color are Saltos tablets/capsules usually?

The official regulatory labeling for Saltos contains a detailed physical description of the medicine, which includes its color, size, shape, and any distinguishing markings. This information is provided to help confirm that the correct dosage form has been dispensed.


Q: Does Saltos affect a person's mood or behavior?

Official safety information lists effects on the Nervous system as a documented adverse reaction category. These can potentially include symptoms like dizziness and nervousness, which may influence behavior or mood.


Q: Does Saltos interact with medications used for depression or anxiety?

Yes, regulatory documents confirm a documented interaction with certain medicines used for depression, specifically Selective Serotonin Reuptake Inhibitors (SSRIs). Taking Saltos with an SSRI is described as increasing the risk of serious gastrointestinal bleeding.


Q: Is Saltos safe for people who have diabetes?

Regulatory warnings for the NSAID class recommend that people with underlying conditions, such as high blood pressure or diabetes, receive careful monitoring during treatment. This monitoring helps manage potential risks associated with the medicine's use in these populations.


Q: Is Saltos associated with problems sleeping (insomnia)?

Official product information lists difficulty falling asleep or staying asleep (insomnia) as a potential side effect of Saltos. This information is based on data collected during clinical trials and post-marketing surveillance.


Q: Do any official sources mention the potential for dependence with Saltos?

Regulatory labeling classifies Saltos as a Non-Opioid Analgesic and does not contain the specific warnings for dependence or abuse typically found with controlled substances. This means official sources do not associate this medicine with the potential for addiction or withdrawal syndrome.

How should Saltos be stored and disposed of?

How to Store and Dispose of Saltos?

Storage and disposal of Saltos (Active Substance A) must adhere strictly to the conditions specified in official regulatory labeling.

Storage Requirements

Saltos must be stored at Controlled Room Temperature, typically defined as 20^circ to 25 C (68^circ to 77 F), and must be protected from excessive heat, moisture, and light. To maintain product integrity, the medicine must be kept in its original container, which should be tightly closed when not in use. The Oral Solution formulation must not be frozen. As a mandatory safety requirement, all forms must be stored out of the sight and reach of children.

️ Disposal Instructions

Unused or expired Saltos should be disposed of through a dedicated drug take-back program when available. If a take-back program is unavailable, official guidelines recommend mixing the product with an undesirable substance, placing it in a sealed container, and then throwing it into the household trash. It is explicitly stated that the medicine should not be flushed down the toilet or poured into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Saltos found in:

A-Z Index: